Double-Blind Maintenance Safety and Effectiveness Findings From the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) Study

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 49, Issue 6, 2010, Pages 583-594

  Findling, Robert L ^a   Johnson, Jacqueline L ^j   McClellan, Jon ^b   Frazier, Jean A ^d,k   Vitiello, Benedetto ^f   Hamer, Robert M ^j   Lieberman, Jeffrey A ^i,j   Ritz, Louise ^g   McNamara, Nora K ^a   Lingler, Jacqui ^a   Hlastala, Stefanie ^b   Pierson, Leslie ^c   Puglia, Madeline ^j   Maloney, Ann E ^h,j   Kaufman, Emily Michael ^e,k   Noyes, Nancy ^h,k   Sikich, Linmarie ^j  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e Clinical Psychology Program   (United States)

^f NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^g NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^h Maine Medical Center Research Institute

ⁱ Och Spine at New York Presbyterian Hospitals

^j UNIVERSITY OF NORTH CAROLINA   (United States)

^k CAMBRIDGE HEALTH ALLIANCE   (United States)

more..

Author keywords

adolescent; antipsychotic; schizoaffective disorder; schizophrenia; treatment

Indexed keywords

BENZATROPINE; CITALOPRAM; CLONAZEPAM; DIPHENHYDRAMINE; FLUOXETINE; LITHIUM; LORAZEPAM; MOLINDONE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; PROPRANOLOL; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRIHEXYPHENIDYL; VALPROIC ACID;

ACNE; ADOLESCENT; ADULT; AGITATION; AKATHISIA; ALLERGY; ANXIETY; ARTICLE; ATTENTION DISTURBANCE; CHILD; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INCREASED APPETITE; INSOMNIA; IRRITABILITY; MANIA; NERVOUSNESS; NEUROLOGIC DISEASE; NOSE CONGESTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SORE THROAT; SUICIDAL IDEATION; SYSTOLIC BLOOD PRESSURE; TARDIVE DYSKINESIA; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ADOLESCENT; AKATHISIA, DRUG-INDUCED; BENZODIAZEPINES; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LONG-TERM CARE; MALE; MOLINDONE; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; RISK FACTORS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; WEIGHT GAIN; YOUNG ADULT;

EID: 77952319138     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1097/00004583-201006000-00007     Document Type: Article

References (17)

1. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 40 suppl (2001) 4S-23S
2. Frazier J.A., McClellan J., Findling R.L., et al. Treatment of Early-Onset Schizophrenia Spectrum disorders (TEOSS): demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry 46 (2007) 979-988
3. Sikich L., Frazier J.A., McClellan J., et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. Am J Psychiatry 165 (2008) 1420-1431
4. Johnsen E., and Jørgensen H.A. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry 8 (2008) 31
5. McClellan J., Sikich L., Findling R.L., et al. Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry 46 (2007) 969-978
6. Kay S.R., Fiszbein A., and Opler L.A. The Positive And Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 262-276
7. National Institute of Mental Health. Special feature: rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 21 (1985) 765-770
8. Overall J.E., and Pfefferbaum B. The brief psychiatric rating scale for children. Psychopharmacol Bull 18 (1982) 10-16
9. Hodges K. Child and Adolescent Functional Assessment Scale (1995), Department of Psychology, Eastern Michigan University, Ypsilanti
10. Kalachnik J.E. Standardized Monitoring for Psychopharmacologic Medication Side Effects. Manual for the Monitoring of Side Effects Scale (MOSES) (2001), University of South Carolina, School of Medicine, Columbia
11. Simpson G.M., and Angus J.W.S. A rating scale for extrapyramidal effects. Acta Psychiatr Scand 212 (1970) 111-199
12. Barnes T.R. A rating scale for drug-induced akathisia. Br J Psychiatry 154 (1989) 672-676
13. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data (2000), US Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, MD. http://www.cdc.gov/growthcharts/
14. Lieberman J.A., Stroup T.S., McEvoy J.P., et al., Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
15. Jones P.B., Barnes T.R., Davies L., et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63 (2006) 1079-1087
16. Kahn R.S., Fleischhacker W.W., Boter H., et al., EUFEST Study Group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371 (2008) 1085-1097
17. McEvoy J.P., Lieberman J.A., Perkins D.O., et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164 (2007) 1050-1060